A Randomized, Double-Blind, Active Placebo-Controlled Phase 2 Pilot Study of MDMA-assisted Psychotherapy in People With Chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD)
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2017
Price : $35 *
At a glance
- Drugs Methylenedioxymetamfetamine (Primary)
- Indications Post-traumatic stress disorders
- Focus Therapeutic Use
- Acronyms MP-9
- 23 Oct 2013 Planned end date changed from 1 Dec 2016 to 1 Aug 2015 as reported by ClinicalTrials.gov.
- 17 Sep 2013 Planned end date changed from 1 Dec 2013 to 1 Dec 2016 as reported by ClinicalTrials.gov.
- 25 Sep 2012 New trial record